On Wednesday, Structure Therapeutics (NASDAQ:GPCR) shares maintained Overweight rating and a price target of $93.00, as confirmed by Piper Sandler. The firm highlighted GPCR's announcement of ACCG-2671 as their leading oral small molecule for obesity treatment. This candidate has shown pre-clinical efficacy on par with Novo Nordisk (NYSE:NVO)'s cagrilintide, but with the advantage of being an oral, once-daily treatment.
Structure Therapeutics is preparing to begin a Phase 1 single ascending dose/multiple ascending dose (SAD/MAD) trial for ACCG-2671 at the end of 2025, with topline results expected by the end of 2026. Moreover, the company is planning Phase 2 development of the drug as both a standalone treatment and in combination with an oral GLP-1 receptor agonist.
The firm's strategy includes developing a range of potent oral amylin molecules, with various amylin/calcitonin ratios, aiming to establish a strong presence in the metabolic disorder market. Piper Sandler believes that the scarcity of amylin treatments adds significant value to GPCR's portfolio.
Furthermore, GPCR anticipates that upcoming results from their CagriSema trials over the next year could further validate the mechanism of action (MoA) of amylin and its potential in combination with GLP-1 therapies.
Piper Sandler remains optimistic about GPCR's prospects, particularly looking forward to the Phase 2b ACCESS and ACCESS II trials for GSBR-1290, with results expected by the end of 2025, and the initiation of clinical trials for ACCG-2671.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.